Cervical Arthroplasty
Taken to Another Level
®
®
Only FDA Approved Cervical Disc
for One & Two Levels
®
MOBI-C HAD LOWER RATES OF
ADJACENT LEVEL DEGENERATION
The deterioration of adjacent segments at 24 months
compared to baseline was:
• 2.9% for Mobi-C compared to 18.1% for ACDF
at the inferior level.
• 13.1% for Mobi-C compared to 33.3% for ACDF
at the superior level.
MOBI-C HAD FEWER
SECONDARY SURGERIES
3.1% of Mobi-C patients compared to 11.4% of ACDF
patients reported secondary surgeries at the index
levels through 24 months.
40%
35%
30%
25%
20%
15%
10%
5%
0%
%
of
Randomized
Patients
with
Available
Data
Adjacent Segment Degeneration at 24 Months
TWO-LEVEL
Inferior Adjacent Level
18.1%
2.9%
33.3%
13.1%
Superior Adjacent Level
Mobi-C
ACDF
FOR TWO LEVELS AT TWO YEARS:
80%
70%
60%
50%
40%
30%
20%
10%
0%
%
of
Randomized
Patients
with
Available
Data
Overall Trial Success at 24 Months
TWO-LEVEL
Mobi-C
ACDF
69.7%
37.4%
*
(p<0.0001)
*Fisher Exact test used to compare treatments to establish superiority.
16%
14%
12%
10%
8%
6%
4%
2%
0%
%
of
Randomized
Patients
Secondary Surgeries Within 24 Months
TWO-LEVEL
Mobi-C
ACDF
3.1%
11.4%
*
(p=0.0044)
*Fisher Exact test used to compare treatments.
Please refer to the Mobi-C Summary of Safety and
Effectiveness (PMA P110002, PMA P110009) at
www.fda.gov for complete study results.
MOBI-C IS SUPERIOR TO
ACDF AT TWO LEVELS
Mobi-C demonstrated statistical superiority in
overall trial success compared to ACDF at 24 months.
For more information visit:
www.cervicaldisc.com
www.ldr.com
